STOCKHOLM, Sweden, September 7 /PRNewswire/ -- BSP- Biological Signal Processing Ltd. (www.bsp.co.il) announced today the presentation of results from a large-scale clinical study of its HyperQ(TM) Stress System at the 2005 European Society of Cardiology Congress. The encouraging results provide positive scientific evidence that stress-induced ischemia could be accurately detected using the HyperQ(TM) Stress System. The system uses sophosticated analysis of the ECG signal to provide a reliable measure for cardiac ischemia, based on the high-frequency components of the ECG. The HyperQ(TM) Stress system, cleared for sale by the FDA and carries the CE mark, is the first commercially available device that allows high-frequency mid-QRS analysis in addition to conventional stress ECG, offering an accurate and effective noninvasive tool for the detection of ischemic heart disease.
The presented study assessed the diagnostic efficacy of the HyperQ(TM) Stress System in detecting exercise-induced ischemia in 900 patients referred for SPECT myocardial perfusion imaging (nuclear mapping of the cardiac muscle). Results indicated that the HyperQ(TM) analysis significantly improved the diagnostic ability of the Stress Test, reaching impressive sensitivity of 78% and specificity of 86%.
"We have successfully demonstrated that the HyperQ(TM) system offers a superior tool for Ischemia detection, without any modifications to the traditional stress test protocol" said Dr. Haim Silber, who was the principal investigator in the study and who presented it at the conference.
The High Frequency QRS analysis is an innovative method for noninvasive diagnosis of Myocardial Ischemia. "The technology developed by BSP to extract the HyperQ(TM) Signal can be integrated within a wide range of clinical systems, offering unmatched detection capabilities for ischemic conditions", said Dr. Amir Beker, BSP's founder and CEO.
BSP has been awarded a grant by the Office of the Chief Scientist (OCS) of Israel's Ministry of Industry and Trade for supporting a NIS 1.7 million R&D budget. The funds have been granted for the development of BSP's next application, the HyperQ Rest Monitor.
BSP was founded in 2000, consisting of top signal processing experts, biomedical engineers and clinicians. BSP's chief scientist is Prof. Shimon Abboud, a pioneering researcher in the field of high-frequency ECG and a world leader in ECG signal analysis for more than 25 years.
Amir Beker, CEO
BSP - Biological Signal Processing Ltd